Lion Point Capital, LP
CIK 1643354 · View on SEC EDGAR ↗
- Portfolio value
- $20.9M
- Positions
- 35
- As of
- June 30, 2026
#8,898 of 9,443 by 13F value · top 94.2%
Portfolio value QoQ: +24.9% 13F does not disclose cash
- Top 10 holdings weight
- 55.01%
- Top 25 holdings weight
- 90.10%
- Positions above 1%
- 30
- Effective number of positions
- 23.8
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 2.69% Est. buys $1,670,408 · sells $506,436
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 74.5% still held
- New positions
- 1
- Increased
- 0
- Decreased
- 0
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +287.3% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.6% · Options excluded: 0.0%
Sector breakdown
Healthcare
92.0%
Other/Unmapped
8.0%
Full portfolio 35 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| Unknown issuer (CUSIP: 22978P205) | $1,670,408 | 7.99% | 52,928 | Up ×1 | |||
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $1,489,816 | 7.13% | 4,450 | $56,070 | |||
| MLTX MoonLake Immunotherapeutics - Class A Ordinary Shares | $1,314,225 | 6.29% | 67,500 | $56,025 | |||
| FENC Fennec Pharmaceuticals Inc. - Common Stock | $1,208,666 | 5.78% | 112,434 | $517,197 | |||
| RPRX Royalty Pharma plc - Class A Ordinary Shares | $1,199,898 | 5.74% | 21,400 | $173,340 | |||
| CMPS COMPASS Pathways Plc - American Depository Shares | $1,132,000 | 5.41% | 80,000 | $689,600 | |||
| MIST Milestone Pharmaceuticals Inc. - Common Shares | $1,098,800 | 5.26% | 820,000 | $123,000 | |||
| BNTC Benitec Biopharma Inc. - Common Stock | $829,560 | 3.97% | 62,000 | $169,260 | |||
| SNDX Syndax Pharmaceuticals, Inc. - Common Stock | $786,960 | 3.76% | 36,000 | $-54,000 | |||
| BHVN Biohaven Ltd. Common Shares | $769,296 | 3.68% | 51,700 | $331,914 | |||
| GERN Geron Corporation - Common Stock | $739,840 | 3.54% | 578,000 | $-121,380 | |||
| QURE uniQure N.V. - Ordinary Shares | $677,082 | 3.24% | 14,700 | $436,737 | |||
| ARDX Ardelyx, Inc. - Common Stock | $656,115 | 3.14% | 128,650 | $-114,499 | |||
| LNTH Lantheus Holdings, Inc. - Common Stock | $610,170 | 2.92% | 5,500 | $192,995 | |||
| IRON Disc Medicine, Inc. - Common Stock | $592,434 | 2.83% | 8,100 | $74,520 | |||
| SRPT Sarepta Therapeutics, Inc. - Common Stock | $512,145 | 2.45% | 28,500 | $-108,015 | |||
| HUMA Humacyte, Inc. - Common Stock | $507,260 | 2.43% | 650,000 | $112,905 | |||
| KURA Kura Oncology, Inc. - Common Stock | $504,620 | 2.41% | 46,000 | $130,640 | |||
| VTRS Viatris Inc. - Common Stock | $439,876 | 2.10% | 27,700 | $65,649 | |||
| DYN Dyne Therapeutics, Inc. - Common Stock | $399,780 | 1.91% | 18,000 | $73,440 | |||
| BBIO BridgeBio Pharma, Inc. - Common Stock | $372,400 | 1.78% | 5,000 | $1,100 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $369,733 | 1.77% | 9,100 | $83,083 | |||
| PCRX Pacira BioSciences, Inc. - Common Stock | $342,495 | 1.64% | 13,500 | $37,395 | |||
| RGNX REGENXBIO Inc. - Common Stock | $318,668 | 1.52% | 26,600 | $95,760 | |||
| RCKT Rocket Pharmaceuticals, Inc. - Common Stock | $294,120 | 1.41% | 86,000 | $-13,760 | |||
| JANX Janux Therapeutics, Inc. - Common Stock | $291,840 | 1.40% | 19,000 | $27,740 | |||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $283,290 | 1.36% | 10,500 | $-1,155 | |||
| GHRS GH Research PLC - Ordinary Shares | $274,176 | 1.31% | 10,200 | $130,764 | |||
| MCRB Seres Therapeutics, Inc. - Common Stock | $249,087 | 1.19% | 31,570 | $-30,939 | |||
| AZTA Azenta, Inc. - Common Stock | $247,544 | 1.18% | 9,700 | $42,583 | |||
| JSPR Jasper Therapeutics, Inc. - Class A Common Stock | $195,765 | 0.94% | 465,000 | $-211,668 | |||
| INVA Innoviva, Inc. - Common Stock | $186,222 | 0.89% | 8,200 | $-4,838 | |||
| IPHA Innate Pharma S.A. - American Depositary Shares | $149,318 | 0.71% | 81,151 | $45,445 | |||
| ARQT Arcutis Biotherapeutics, Inc. - Common stock | $137,655 | 0.66% | 5,250 | $13,965 | |||
| SPRB Spruce Biosciences, Inc. - Common Stock | $54,000 | 0.26% | 1,000 | $-11,350 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 22978P205) | $1,670,408 | 52,928 | 7.99% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| CMPS | Price move only | +0 | +$690K |
| FENC | Price move only | +0 | +$517K |
| QURE | Price move only | +0 | +$437K |
| BHVN | Price move only | +0 | +$332K |
| JSPR | Price move only | +0 | -$212K |
| LNTH | Price move only | +0 | +$193K |
| RPRX | Price move only | +0 | +$173K |
| BNTC | Price move only | +0 | +$169K |
| GHRS | Price move only | +0 | +$131K |
| KURA | Price move only | +0 | +$131K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| AVDL | Dec. 31, 2025 | 59,700 | $911,619 | No longer tracked |
| KNSA | Dec. 31, 2025 | 23,400 | $908,622 | 93.1% |
| INSM | Dec. 31, 2025 | 6,250 | $900,063 | -26.2% |
| CUE | June 30, 2026 | 2,202,854 | $506,436 | -14.9% |
| DAWN | March 31, 2026 | 42,000 | $391,440 | No longer tracked |
| BLUE | June 30, 2025 | 78,912 | $385,091 | No longer tracked |
| VTYX | March 31, 2026 | 41,500 | $374,745 | No longer tracked |
| NERV | March 31, 2026 | 35,000 | $140,700 | -20.9% |
| SPRB | June 30, 2025 | 75,000 | $21,758 | -87.5% |
| MRSN | March 31, 2026 | 100 | $2,893 | No longer tracked |